Il y a eu 50 transactions d'initiés récentes enregistrées pour Verona Pharma plc (VRNA), dont 15 achats et 34 ventes. Le total des achats d'initiés s'élève à $431.64K et le total des ventes d'initiés à $39.14M.
Les initiés notables ayant une activité récente comprennent Fisher Andrew, Hahn Mark W, Zaccardelli David. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — VRNA
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2025-06-16 |
Fisher Andrew |
General Counsel |
Vente Informative |
80,000 |
$11.53 |
$922K |
359,999 |
| 2025-06-11 |
Hahn Mark W |
Chief Financial Officer |
Vente Informative |
400,000 |
$11.40 |
$4.56M |
12,278,992 |
| 2025-06-11 |
Zaccardelli David |
President and CEO |
Vente Informative |
400,000 |
$11.40 |
$4.56M |
13,190,168 |
| 2025-05-29 |
Hahn Mark W |
Chief Financial Officer |
Vente Informative |
204,864 |
$9.33 |
$1.91M |
12,678,992 |
| 2025-05-29 |
Zaccardelli David |
President and CEO |
Vente Informative |
208,696 |
$9.33 |
$1.95M |
13,590,168 |
| 2025-05-28 |
Hahn Mark W |
Chief Financial Officer |
Vente Informative |
162,704 |
$9.30 |
$1.51M |
12,883,856 |
| 2025-05-28 |
Zaccardelli David |
President and CEO |
Vente Informative |
157,704 |
$9.30 |
$1.47M |
13,798,864 |
| 2025-05-27 |
Hahn Mark W |
Chief Financial Officer |
Vente Informative |
32,432 |
$9.53 |
$308.98K |
13,046,560 |
| 2025-05-27 |
Zaccardelli David |
President and CEO |
Vente Informative |
33,600 |
$9.53 |
$320.18K |
13,956,568 |
| 2025-05-20 |
Sinha Vikas |
Director |
Exercice d'Options (Vente) |
160,000 |
$0.50 |
$80.61K |
384 |
| 2025-05-15 |
Fisher Andrew |
General Counsel |
Vente Informative |
80,000 |
$8.57 |
$685.6K |
359,999 |
| 2025-05-15 |
Fisher Andrew |
General Counsel |
Exercice d'Options |
80,000 |
$2.01 |
$160.9K |
439,999 |
| 2025-05-14 |
Ackermann Christina |
Director |
Vente Informative |
40,000 |
$8.44 |
$337.6K |
41,880 |
| 2025-05-06 |
Rickard Kathleen A. |
Chief Medical Officer |
Vente Informative |
114,984 |
$8.82 |
$1.01M |
2,546,472 |
| 2025-05-02 |
Hahn Mark W |
Chief Financial Officer |
Vente Informative |
400,000 |
$9.09 |
$3.64M |
13,078,992 |
| 2025-05-02 |
Zaccardelli David |
President and CEO |
Vente Informative |
400,000 |
$9.09 |
$3.64M |
13,990,168 |
| 2025-05-01 |
Ebsworth David R |
Director |
Exercice d'Options |
140,000 |
$1.93 |
$270.73K |
- |
| 2025-05-01 |
Hahn Mark W |
Chief Financial Officer |
Exercice d'Options (Vente) |
200,000 |
- |
- |
1,000,000 |
| 2025-05-01 |
Zaccardelli David |
President and CEO |
Exercice d'Options (Vente) |
200,000 |
- |
- |
1,000,000 |
| 2025-05-01 |
Rickard Kathleen A. |
Chief Medical Officer |
Exercice d'Options (Vente) |
50,000 |
- |
- |
250,000 |
| 2025-04-29 |
Sinha Vikas |
Director |
Vente Informative |
4,952 |
$8.92 |
$44.18K |
74,440 |
| 2025-04-29 |
Hahn Mark W |
Chief Financial Officer |
Exercice d'Options (Vente) |
229,512 |
- |
- |
445,488 |
| 2025-04-29 |
Zaccardelli David |
President and CEO |
Exercice d'Options (Vente) |
229,512 |
- |
- |
445,488 |
| 2025-04-29 |
Rickard Kathleen A. |
Chief Medical Officer |
Exercice d'Options (Vente) |
86,064 |
- |
- |
167,056 |
| 2025-04-29 |
Fisher Andrew |
General Counsel |
Exercice d'Options (Vente) |
86,064 |
- |
- |
167,056 |
| 2025-04-29 |
Sinha Vikas |
Director |
Exercice d'Options (Vente) |
120,384 |
$1.70 |
$204.65K |
- |
| 2025-04-25 |
Ebsworth David R |
Director |
Attribution de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Shah Mahendra |
Director |
Attribution de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Sinha Vikas |
Director |
Attribution de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Edwards Martin |
Director |
Attribution de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Ackermann Christina |
Director |
Attribution de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Ullman Anders |
Director |
Attribution de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Cunningham Kenneth |
Director |
Attribution de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Deschamps Lisa |
Director |
Attribution de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Brady James Aloysius |
Director |
Attribution de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Austwick Michael |
Director |
Attribution de RSU |
96,000 |
- |
- |
96,000 |
| 2025-03-19 |
Fisher Andrew |
General Counsel |
Don (Reçu) |
1 |
- |
- |
300,001 |
| 2025-03-12 |
Rickard Kathleen A. |
Chief Medical Officer |
Vente Informative |
79,264 |
$8.35 |
$661.94K |
2,608,976 |
| 2025-02-26 |
Ebsworth David R |
Director |
Exercice d'Options (Vente) |
96,000 |
$2.67 |
$256.32K |
- |
| 2025-02-03 |
Hahn Mark W |
Chief Financial Officer |
Retenue Fiscale RSU |
166,888 |
$7.16 |
$1.2M |
13,326,848 |
| 2025-02-03 |
Zaccardelli David |
President and CEO |
Retenue Fiscale RSU |
166,728 |
$7.16 |
$1.19M |
14,238,024 |
| 2025-02-03 |
Rickard Kathleen A. |
Chief Medical Officer |
Retenue Fiscale RSU |
33,240 |
$7.16 |
$238.08K |
2,688,240 |
| 2025-02-01 |
Hahn Mark W |
Chief Financial Officer |
Attribution de RSU |
200,000 |
- |
- |
13,493,736 |
| 2025-02-01 |
Zaccardelli David |
President and CEO |
Attribution de RSU |
200,000 |
- |
- |
14,404,752 |
| 2025-02-01 |
Rickard Kathleen A. |
Chief Medical Officer |
Attribution de RSU |
50,000 |
- |
- |
2,721,480 |
| 2024-12-06 |
Hahn Mark W |
Chief Financial Officer |
Vente Informative |
183,728 |
$5.01 |
$920.31K |
13,293,736 |
| 2024-12-06 |
Zaccardelli David |
President and CEO |
Vente Informative |
162,800 |
$5.01 |
$815.4K |
14,204,752 |
| 2024-12-05 |
Hahn Mark W |
Chief Financial Officer |
Vente Informative |
640,048 |
$5.01 |
$3.2M |
13,477,464 |
| 2024-12-05 |
Zaccardelli David |
President and CEO |
Vente Informative |
640,264 |
$5.01 |
$3.21M |
14,367,552 |
| 2024-12-04 |
Hahn Mark W |
Chief Financial Officer |
Vente Informative |
58,184 |
$5.00 |
$291K |
14,117,512 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
